
GLP-1 therapy significantly reduces migraine frequency
A pilot study presented at the European Academy of Neurology congress suggests that GLP-1 agonists, drugs typically used for diabetes and obesity, may also significantly reduce migraine frequency by nearly half, possibly by lowering intracranial pressure.


